See editorial on page 1404. N onalcoholic fatty liver disease (NAFLD) has emerged as the most prevalent form of liver disease in the United States 1 and cardiovascular mortality is the most common cause of death among patients with NAFLD. 2 The beneficial impact of modest alcohol use on mortality in the general population is largely mediated by a decrease in cardiovascular disease. 3 Although this suggests that many patients with liver disease may benefit from modest alcohol use, even modest alcohol use often is discouraged in patients with concomitant liver disease owing to concern for potential synergistic hepatic injury. More than one third of the adult population in the United States is affected by NAFLD and approximately two-thirds drink alcohol, 4 the vast majority of whom drink in moderation, however, no clear guidelines exist on how to counsel these patients.
There is significant overlap in the pathways by which alcohol and NAFLD cause disease. [5] [6] [7] However, these overlapping pathways largely stem from evaluation of pathologic alcohol intake, and modest alcohol use clearly mitigates insulin resistance, 8 which is a driving factor in NAFLD. Multiple studies have shown a lower incidence of NAFLD among modest drinkers, although the beneficial effect may vary based on race and the degree of underlying obesity. 9, 10 In addition, previous cross-sectional studies of patients with NAFLD, including a publication by the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN), have suggested that modest alcohol use is associated with less severe histology including less NASH and fibrosis, 11, 12 however, modest alcohol users tend to have higher physical activity levels and less obesity, which are potential confounding factors. Furthermore, cross-sectional studies limit the ability to make temporal associations and the direction of causality cannot be determined because patients with more severe disease may be more likely to abstain from alcohol.
Therefore, the longitudinal association between modest alcohol intake and NAFLD remains unclear. In this study, we evaluated the effect of modest alcohol use compared with abstinence on NAFLD histology over time using paired liver biopsy specimens after adjusting for factors associated with alcohol use.
Methods

Study Design and Participants
This was a longitudinal cohort study of adult participants recruited into the studies conducted by the NASH CRN, a multicenter network sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases. Participants for this study were drawn from 3 groups within the NASH CRN studies, as follows: (1) the adult NAFLD Database study, (2) adults on placebo in the Pioglitazone vs Vitamin E vs Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis (PIVENS) trial, and (3) adults on placebo in the Farnesoid X Receptor Ligand Obeticholic Acid in NASH Treatment (FLINT) Trial. Informed consent was obtained from all participants, and the studies were approved by the Institutional Review Boards at each clinical center and the Data Coordinating Center.
The adult NAFLD Database is a prospective observational study of participants at least 18 years of age with either a histologic diagnosis of NAFLD or cryptogenic cirrhosis, suspected NAFLD based on imaging studies, or clinical evidence of cryptogenic cirrhosis. Exclusion criteria included clinical evidence of alcoholic liver disease or alcohol consumption during the 2 years before entry of more than 20 g/d for men and 10 g/d for women, and evidence of other forms of chronic liver disease. 13 The PIVENS trial was conducted from 2005 to 2008 and included nondiabetic, noncirrhotic adults with definite or possible steatohepatitis. 14, 15 The FLINT trial was conducted from 2011 to 2014 and included noncirrhotic adults with NASH. 16 This study included all participants in these 3 studies who did not receive specific pharmacologic therapy for NASH, were aged 21 years or older, and had 2 or more liver biopsies and alcohol use history within 2 years of the initial biopsy. The median time between baseline biopsy and alcohol use history was 63 days, and between biopsy and laboratory data acquisition was 59 days. For the second biopsy, the median number of days between the biopsy and alcohol history was 19 days, and the median number of days between the biopsy and the laboratory data was 22 days. The average number of follow-up visits over the study period was 4.26, and the interval depended on the study cohort from which the patient was recruited. Patients who reported more than 20 g of alcohol in a typical drinking day, 6 or more drinks on 1 occasion at least monthly, or with biopsies less than 1 year apart were excluded at baseline. Patients with no follow-up history were excluded and nondrinkers at baseline with a previous history of alcohol drinking were excluded. Of 530 identified patients, 285 were included in this analysis (Figure 1 ). A total of 172 patients in this longitudinal study (60%) overlapped with the previous cross-sectional study of modest alcohol use performed by the NASH CRN.
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Alcohol Consumption
The primary exposure of interest was modest alcohol consumption compared with abstinence from alcohol. Alcohol consumption was evaluated at study entry using the Alcohol Use Disorders Identification Test (AUDIT) and Skinner Lifetime Drinking History questionnaires. At follow-up visits the abbreviated AUDIT-Consumption (AUDIT-C) questionnaire was administered. At baseline, participants were asked, "How often do you have a drink containing alcohol?" Those who responded "never" were characterized further based on their response to the question from the Skinner Lifetime Drinking Assessment, "Over the course of your lifetime have you ever had at least 1 drink of alcohol, beer, liquor, wine, or wine coolers per month during a 12-month time period, or at least 3 drinks per day for at least 3 consecutive days?" Nondrinkers who answered yes were considered previous drinkers currently not drinking and were excluded to limit the effect that former drinking, including possible prior heavy drinking, may have on disease severity among nondrinkers. Those who answered no were considered lifetime nondrinkers and included. Participants who drank alcohol were asked, "How many drinks containing alcohol do you have on a typical day when you are drinking?" Those who reported drinking more than 2 drinks on a drinking day were considered more than modest users and excluded. Participants who drank 2 or fewer drinks on a typical day were asked "How often do you have 6 or more drinks on 1 occasion?" Those who reported monthly or more frequent heavy drinking also were considered more than modest users and were excluded.
At each follow-up visit participants were again asked about alcohol use frequency, the amount of drinks on a typical day, and the frequency of heavy drinking using the questions listed earlier. Participants were classified into nondrinkers, modest alcohol users, and more than modest users. 
Histologic Evaluation
Biopsy specimens were evaluated centrally by the NASH CRN Pathology Committee for the following histologic features, according to the validated histologic scoring system by Kleiner et al. 17 For analysis, change in steatosis, lobular inflammation, portal inflammation, and ballooning degeneration were calculated by subtracting the grade at follow-up evaluation from the grade at baseline, and change in fibrosis was calculated by subtracting the stage at follow-up evaluation from the stage at baseline. A diagnosis of NASH was established independent of the NAFLD Activity Score and classified as definite NASH, NAFLD not NASH, or suspicious for NASH ("borderline" NASH) based on central pathology reading as previously defined. 17 NASH resolution was defined as a transition from definite NASH on the initial biopsy to not NASH on the subsequent biopsy.
Clinical and Laboratory Assessment
Demographic data and self-reported physiciandiagnosed comorbidities were obtained via structured interview. Height, weight, and waist and hip measurements were taken in duplicate while standing and wearing light clothing and averaged for analyses. Body mass index (BMI) was calculated as weight (in kilograms) divided by height (in meters) squared. Fasting whole blood samples were obtained via venipuncture after an overnight fast of 8 hours or more and processed for plasma and serum within 2 hours. The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated using the following equation: (fasting glucose
Statistical Analysis
Descriptive statistics were generated on clinical, laboratory, and histologic parameters at baseline. Comparisons between nondrinkers and modest drinkers were made using chi-square tests for categoric variables and the Kruskal-Wallis test for noncategoric measures. Multivariable logistic regression was used to evaluate for variables associated with modest drinking compared with nondrinking status. Reduced model selection using minimization of Akaike's information criterion was performed. Changes in histologic and clinical features from enrollment to follow-up evaluation were assessed using analysis of covariance, regressing change from baseline to time of last biopsy on baseline drinking status and baseline value of the outcome. Odds ratios and P values were calculated using logistic regression models. Change in drinking status at follow-up evaluation was assessed using the McNemar chi-square test. Change in histology assessed by a change in drinking status was assessed using logistic regression models adjusted for potential confounding covariates including age, sex, race, and smoking status. Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC) and Stata release 13 (StataCorp, College Station, TX). A P value less than .05 was the threshold for statistical significance.
Results
Characteristics of the Study Population
A total of 285 patients with NAFLD from the NASH CRN trials were included in the analysis. These included 49 placebo recipients from the PIVENS trial, 49 placebo recipients from the FLINT trial, and 187 subjects followed up in the NASH CRN database cohort who did not receive specific pharmacologic therapy for NAFLD. Participants were a mean age of 47.0 years, predominantly female (70%), white (82%), and obese (mean BMI, 34.7 kg/m 2 ). Diabetes (34.4%) and the metabolic syndrome (69.2%) were common comorbidities. Of the 285 adult participants, 182 were classified as definite NASH (64%), 54 as NAFLD but not NASH (19%), and 49 as borderline NASH (17%). Sixty-five (23%) had no fibrosis, 32% had stage 1 fibrosis, 21% had stage 2 fibrosis, 21% had stage 3 fibrosis, and 3% had stage 4 fibrosis at baseline ( Table 1 ). The means AE SD time between biopsies was 47 AE 26 months.
Baseline Differences by Alcohol Use
At baseline, 117 participants were nondrinkers and 168 were modest drinkers. The majority (78%) of modest drinkers reported drinking alcohol monthly or less frequently. Modest drinkers were more often white (86% vs 76%; P ¼ .04), younger (mean age, 45.9 vs 48.5 y; P ¼ .06), and less likely to be female (66% vs 76%; P ¼ .06) when compared with nondrinkers ( Table 1 ). The mean alkaline phosphatase level was lower in modest drinkers than in nondrinkers at baseline (77 vs 86 U/L; P < .001). BMI, HOMA-IR, and the prevalence of metabolic syndrome were similar between the 2 groups at baseline. Nondrinkers had more definite NASH at baseline compared with modest drinkers (74% vs 57%; P ¼ .01), however, there were no other significant differences in other histologic parameters at baseline including fibrosis stage. In addition, among the 155 patients for whom Patatin-like phospholipase domain containing protein 3 (PNPLA3) genotyping was available, there was no significant difference between the 2 groups. In sensitivity analysis grouping nondrinkers with participants who drank monthly or less and comparing them to more than monthly drinkers (N ¼ 37), more than monthly drinkers were less likely to be female, had lower alkaline phosphatase levels, and had a lower BMI (Supplementary Table 1 ). In an Akaike information criterion minimized model, younger age, white race, ever-smoking status, alanine aminotransferase level, alkaline phosphatase level, g-glutamyltransferase, steatosis grade, and definite NASH histology remained significantly associated with drinking status at baseline (Supplementary Table 2 ).
Baseline Alcohol Use on Changes in Histology and Clinical Factors
Patients who were nondrinkers at baseline had more improvement in steatosis when compared with modest drinkers, with an adjusted mean change in steatosis grade from baseline to follow-up evaluation of -0.49 vs -0.30, respectively (P ¼ .04) ( Table 2 ). Changes in lobular inflammation, hepatocyte ballooning, portal inflammation, and fibrosis stage were not statistically significant. Nondrinkers had more NASH resolution (21% vs 13%; P ¼ .13), however, this was not statistically significant. Nondrinkers had more improvement in aspartate aminotransferase (AST) level compared with modest drinkers (mean change in AST level, -7 vs 2 U/L; P ¼ .04). Changes in alkaline phosphatase level, HOMA-IR, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, and BMI were not statistically significant. The mean change in BMI in nondrinkers compared with modest drinkers was -0.27 vs 0.23 kg/m 2 (P ¼ .14) ALT, alanine aminotransferase; IQR, interquartile range; NAS, NAFLD Activity Score.
( Table 2) . On sensitivity analysis, more than monthly drinkers had more improvement in portal inflammation compared with those who drank monthly or less (-0.07 vs 0.17 grades; P ¼ .02) (Supplementary Table 3) . Additional sensitivity analyses, among patients with a high-risk genotype, PNPLA3 GC and GG (N ¼ 111), showed no significant difference in mean change in steatosis grade, AST, or odds of NASH resolution by baseline drinking status (Supplementary Table 4 ).
Longitudinal Alcohol Use Pattern and Change in Histology
Fourteen nondrinkers reported modest drinking at follow-up evaluation and 55 modest drinkers reported nondrinking status at follow-up evaluation. Modest drinkers at baseline were much more likely to change drinking status than nondrinkers (33% vs 12%, respectively; P < .001). Modest drinkers who stopped drinking Changes in scores are presented as adjusted means (adjusted for the baseline value) and 95% CIs. P values and mean changes from baseline were calculated using analysis of covariance, regressing change from baseline to time of last biopsy on baseline drinking status and baseline value of the outcome. Odds ratios and P values were calculated using logistic regression models. Improvement was defined as a 1 point or more decrease in the histologic grade or score. ALT, alanine aminotransferase; GGT, g-glutamyltransferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NAS, NAFLD Activity Score.
at follow-up evaluation (n ¼ 55) had more favorable changes in weight compared with modest drinkers who continued modest drinking at follow-up evaluation, albeit not statistically significant (mean change in weight AE SD, -0.3 kg AE 8.6 vs 0.9 kg AE 9.0; P ¼ .34). Four drinking categories were examined, consistent nondrinkers, consistent modest drinkers, modest drinkers who became nondrinkers, and nondrinkers who became modest drinkers. Among participants with NASH at baseline (n ¼ 182), consistent nondrinkers were most likely to have NASH resolution (22% vs 11% among consistent modest drinkers). In logistic regression models adjusted for sex, age, race, and smoking history, consistent modest drinkers were significantly less likely to have NASH resolution (adjusted odds ratio, 0.32; 95% CI, 0.11-0.92; P ¼ .04). Modest drinkers who reported nondrinking at follow-up evaluation had the second highest proportion with NASH resolution at 17%. The adjusted mean change in steatosis grade was similarly better in consistent nondrinkers compared with consistent modest drinkers (adjusted mean difference, 0.26 grades; 95% CI, 0.05-0.48; P ¼ .02) ( Table 3 ). Changes in lobular inflammation, hepatocyte ballooning, and fibrosis stage were not significantly different between the groups. Nondrinkers who became modest drinkers had significantly more improvement in portal inflammation (adjusted mean difference, -0.35 grades; 95% CI, -0.68 to -0.02; P ¼ .04), however, only 14 participants transitioned from nondrinking to modest drinking at follow-up evaluation.
Discussion
By using a well-characterized, longitudinal cohort of NAFLD patients with paired liver biopsy specimens an average of 4 years apart, we found that modest alcohol use at baseline was associated with less improvement in steatosis grade and AST level when compared with nondrinkers. Overall, NAFLD activity improved without pharmacologic intervention in the entire cohort and likely was owing to greater attention to healthy lifestyle. Fourteen nondrinkers who became modest drinkers at follow-up evaluation had greater improvement in portal inflammation than consistent nondrinkers. Conversely, consistent modest drinkers had significantly less NASH resolution and less improvement in steatosis compared with consistent nondrinkers on adjusted analysis. These data challenge the previously published literature that suggested a potential benefit from modest alcohol use in patients with NAFLD and warrant further study on the impact of modest alcohol use in NAFLD.
Previous cross-sectional studies have suggested an association between modest alcohol use and lower odds of NASH and lower fibrosis stage. 11, 12, 18, 19 Importantly, in a cross-sectional design the predictor and outcome are measured at the same time, which precludes determination of the direction of causality. In addition, many previous studies were limited in the ability to adjust for confounding factors and modest alcohol drinkers are more likely to be non-Hispanic white, have higher socioeconomic status, and increased physical activity, which may account for the cross-sectional association with less severe disease. 20 By comparing changes in a person over time, our study was better able to limit the effect of confounding and directly approximate the effect of alcohol in a longitudinal study. Importantly, a recent study of Mendelian randomization, which used a genetic variant associated with alcohol use as a proxy for alcohol use, thereby limiting measurement bias and confounding, found that the genotype associated with light to moderate alcohol use had no benefit on histologic NAFLD and was associated with increased steatosis, lobular inflammation, and NAS. 21 The current study extends upon the previous crosssectional analysis from the NASH CRN and 60% of our study population overlapped with the prior study. Importantly, the baseline characteristics of participants in the current study were similar to the previous study, except for less advanced fibrosis in the current study. This difference is likely related to 2 factors: patients with advanced fibrosis are unlikely to have a second liver biopsy, and our study included patients from the FLINT trial, which excluded cirrhotic patients.
Our study had several noteworthy findings and strengths. First, by performing a longitudinal study with adjusted analysis we were able to limit confounding. Although we showed again that nondrinkers had more NASH at baseline on unadjusted analysis, this likely was related to their increased age, and differences in race, sex, or lifestyle factors. However, when we evaluated longitudinal within-person differences, adjusted for confounders, we showed less improvement in steatosis and less resolution of NASH in modest drinkers. Second, our finding of no benefit from modest alcohol was consistent across biochemical, anthropometric, and histologic factors. Third, our study generates important hypotheses regarding the potential benefit of transitioning from modest drinker to nondrinker through cessation of alcohol use including greater odds of histologic improvement and weight loss, which may mediate this improvement. 22 Finally, although the differences noted in our study were modest, even finding no benefit from modest alcohol use is noteworthy because it challenges the majority of the currently published literature.
Although this study represents a rigorous evaluation of modest alcohol use compared with abstention on changes in NAFLD histology, it had certain limitations. Alcohol use was self-reported in our study, which is subject to recall bias, however, we used standardized, validated questionnaires including the Skinner Lifetime Drinking Assessment and the AUDIT-C. Biomarkers of alcohol use are of limited value in quantitation of alcohol consumption and would need to be assessed frequently to be informative, making them impractical for this study with a mean follow-up period of 4 years. 23 Our study was limited also in that most modest drinkers reported drinking monthly or less frequently, however, underreporting of alcohol use is well-recognized on surveys and may be more frequent in a study of liver disease. 24 We performed sensitivity analysis by grouping participants reporting drinking monthly or less with nondrinkers and comparing them with the population that drank 2 to 4 times monthly or more frequently. We saw a trend toward less improvement in steatosis grade and NAS, however, our precision was reduced by the small sample size. Recent studies have suggested that fibrosis stage is the most important prognostic factor in NAFLD 25 and our study period of 4 years may have been inadequate to detect changes in fibrosis. However, the presence of NASH has consistently been shown to predict increased risk for fibrosis progression 26 and therefore our finding of less NASH resolution among consistent modest drinkers is clinically relevant. Although less improvement in steatosis is of unclear prognostic value in NAFLD, population-based studies have suggested that severe steatosis was associated with increased liverrelated mortality. 27 Although we were unable to assess the association between modest alcohol consumption and cardiovascular risk, we did not see any significant changes in measured metabolic risk factors with known associations with cardiovascular disease including lowdensity lipoprotein and high-density lipoprotein cholesterol and insulin resistance. A recent study of a large population-based sample of patients with NAFLD also found no beneficial association between alcohol use and risk factors or subclinical measurements for cardiovascular disease. 28 Our study also did not evaluate For resolution of definite NASH, logistic regression models were adjusted for the following baseline characteristics: age at biopsy (years), sex (female vs male), race (white vs non-white), and ever smoker. N ¼ 178 because only those biopsy specimens with definite NASH at a baseline were included; 4 patients with definite NASH were missing race. For changes in histologic features and NAS, adjusted mean changes and differences in mean changes were calculated using analysis of covariance models, regressing change in histologic feature on drinking status change, baseline value of the histologic feature, and age at biopsy (years), sex (female vs male), race (white vs non-white), and ever smoker (N ¼ 279), due to 6 patients with missing race data in the entire cohort.
long-term outcomes including liver-related and all-cause mortality. Finally, although we adjusted for race as a confounder, our baseline study population was primarily white non-Hispanic. Hispanic patients have an increased frequency of PNPLA3 G alleles, which is associated with increased histologic severity. 6, 29 In conclusion, our longitudinal study found that modest alcohol use was associated with less improvement in NAFLD histology over an average of nearly 4 years of follow-up evaluation. Importantly, our results suggest that cessation of alcohol use may mitigate these changes. The spectrum of NAFLD, particularly the diagnosis of NASH, should be considered in individualized recommendations to patients regarding modest alcohol use. More advanced NAFLD severity may warrant counseling against modest alcohol use. NOTE. Changes in scores are presented as adjusted means (95% CIs). P values and mean changes from baseline were calculated using analysis of covariance, regressing change from baseline to time of last biopsy on baseline drinking status and baseline value of the outcome. Odds ratios and P values were calculated using logistic regression models. Improvement was defined as a 1-point or more decrease in the histologic grade or score. NAS, NAFLD Activity Score.
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